Search results for: Multi-Indication Medicines
Filter search results
HTA in Japan: Failing to Meet International Good Practice?
15 March 2019
…the maximum reduction of 90% is applied. For drugs with rare disease indications, paediatric indications, or which are anti-cancer agents the threshold range is 50% higher, i.e. JPY7.5million to 90%…
Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help? A Summary of a Symposium held at HTAi Rome 2017
31 October 2017
OHE has just published a new briefing entitled ‘Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?’ OHE has just published a new briefing entitled ‘Antimicrobials Resistance: A…
Presentations from ISPOR Europe 2018
23 November 2018
…from Office of Health Economics Should Drug Prices Differ by Indication? Outlining the debate on indication-based pricing and how it has been implemented to date from Office of Health Economics…
Future Cases of Dementia among People Born in 2015 & the Dementia Drug Pipeline
6 October 2015
…indication. This proportion reduces to 1% at phase III, and 0.5% of those that are marketed. Phase success rate calculations revealed that dementia indications have lower success rates than…
OHE Models Future UK Medicines Spending for the ABPI
3 July 2012
…NHS expenditure on medicines. On 2 July, the ABPI released its projections for UK NHS medicines spending in the years to 2015 based on our model. The results project that…
Published: OHE Study Projecting UK Medicines Expenditure
30 September 2013
This research varies from other analyses in using a product-level, rather than a macro, approach. PharmacoEconomics has just published OHE’s study projecting medicines expenditure in the UK to 2015. (…
Just Published: OHE Report on Trends in Scottish Medicines Committee Advice Decisions
25 February 2016
An analysis in the trends in Scottish Medicines Committee (SMC) advice decisions for medicines for the period October 2009 to September 2015 has just been published in an OHE Consulting…
Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS
29 August 2018
OHE Consulting produces a report on Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS. This OHE Consulting Report, published today, reviews “Measurement of Medicines Expenditure in the…
Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies?
12 January 2014
…how this could lead to improved efficiency in the development of medicines, the pricing and use of medicines, and of health systems. This OHE Occasional Paper by Adrian Towse discusses…